Causation, bias and confounding: A hitchhiker's guide to the epidemiological galaxy. Part 2. Principles of causality in epidemiological research: Confounding, effect modification and strength of association

Journal of Family Planning and Reproductive Health Care

Volumn 34, Issue 3, 2008, Pages 185-190

  Shapiro, Samuel ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; DESOGESTREL; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; DIABETES MELLITUS; DRINKING BEHAVIOR; DRUG MEGADOSE; EPIDEMIC; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; RESEARCH; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SUICIDE; UTERINE CERVIX CANCER; VENOUS THROMBOEMBOLISM;

BIAS (EPIDEMIOLOGY); CAUSALITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPIDEMIOLOGIC RESEARCH DESIGN; EPIDEMIOLOGIC STUDIES; HUMANS; RISK ASSESSMENT;

EID: 47149113676     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118908784734873     Document Type: Review

References (39)

1. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 1. Principles of causality in epidemiological research: time order, specification of the study base and specificity. J Fam Plan Reprod Health Care 2008; 34: 83-87.
2. Shapiro S. Causation, bias and confounding: a hitchhiker's guide to the epidemiological galaxy. Part 3: Principles of causality in epidemiological research: statistical stability, dose-and duration-response effects, internal and external consistency, analogy, and biological plausibility. J Fam Plan Reprod Health Care 2008; 34: (in press).
3. Miettinen O. The need for randomization in the study of intended effects. Stat Med 1983; 2: 267-271.
4. Hertz-Picciotto I. Invited commentary. Shifting the burden of proof regarding biases and low magnitude associations. Am J Epidemiol 2000; 131: 946-948.
5. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestogen contraceptives and menopausal treatment. Lancet Oncol 2005; 6: 552-553.
6. International Agency for Research on Cancer (IARC). Combined Oestrogen-Progestin Contraceptives and Combined Oestrogen-Progestin Menopausal Therapy (IARC Monographs on the Evaluation of Carcinogenic Risk to Humans Vol. 91). Lyon, France: IARC, 2008. http://monographs.iarc.fr/ENG/recentpub/ mono91.pdf [Accessed 4 February 2008].
7. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003; 361: 1159-1167.
8. Davey Smith G, Philips AN, Eaton JD. Smoking as an " independent" risk factor for suicide: illustration of an artifact from observational epidemiology. Lancet 1992; 340: 708-712.
9. International Agency for Research on Cancer (IARC). Alcoholic Drinking (IARC Monographs on the Evaluation of Carcinogenic Risk to Humans Vol. 83). Lyon, France: IARC, 1988.
10. Day GL, Blot WJ, Austin DF, Bernstein L, Greenberg RS, Preston-Martin S, et al. Racial differences in the risk of oral and pharyngeal cancer: alcohol, tobacco and other determinants. J Natl Cancer Inst 1993; 85: 465-473.
11. Kupper L, Hogan MD. Interaction in epidemiologic studies. Am J Epidemiol 1978; 108: 447-453.
12. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. Am J Epidemiol 1980; 12: 467-470.
13. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 1997; 56: 141-146.
14. Suissa S, Spitzer WO. Oral contraceptives and the risk of venous thromboembolism: impact of duration of use. Contraception 1998; 57: 64-68.
15. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000; 15: 817-821.
16. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
17. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and the risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312: 83-88.
18. Lewis MA, MacRae KD, Kühl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO. The differential risk of oral contraceptives: the impact of full exposure history. Hum Reprod 1999; 14: 1493-1499.
19. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestogens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception 1996; 54: 5-13.
20. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000; 151: 939-945.
21. Whittemore AS, Haris R, Intyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies II. Invasive epithelial cancer in white women. Am J Epidemiol 1992; 135: 1184-1203.
22. Shapiro S. Is meta-analysis a valid approach to the evaluation of small effects in observational studies? J Clin Epidemiol 1997; 50: 223-229.
23. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289-293.
24. International Agency for Research on Cancer (IARC). Tobacco Smoke and Involuntary Smoking (IARC Monographs on the Evaluation of Carcinogenic Risk to Humans Vol. 44). Lyon, France: IARC, 2004.
25. Belanger CF, Hennekens CH, Rosner B, Speizer FE. The Nurses Health Study. Am J Nurs 1978; 78: 1039-1040.
26. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
27. Shapiro S. Meta-analysis/shmeta-analysis. Am J Epidemiol 1994; 140: 771-778.
28. Greenland C. Can meta-analysis be salvaged? Am J Epidemiol 1994; 140: 783-787.
29. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003; 6: 302-310.
30. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data [Editorial]. Climacteric 2004; 7: 3-7.
31. Garbe E, Suissa S. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004; 19: 8-13.
32. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
33. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 10 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
34. Shapiro S. Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. Endocrine 2004; 24: 203-210.
35. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al; WHI Investigators. Effects of conjugated equine estrogens on breast cancer mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647-1657.
36. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 28: 321-333.
37. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled Trial. JAMA 2004; 291: 1701-1712.
38. Zhang SM, Manson JE, Rexrode KM, Cook NR, Buring JE, Lee IM. Use of oral conjugated estrogen alone and risk of breast cancer. Am J Epidemiol 2007; 165: 524-529.
39. Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007; 369: 1703-1710.